Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free kros Stock Alerts $58.98 +1.12 (+1.94%) (As of 02:02 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 2EstimatedActual EPS (Mar. 1) -$1.34 Beat By $0.03 Consensus EPS (Mar. 1) -$1.37 Get Keros Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for KROS and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueKROS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.KROS Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Keros Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244($1.34)($1.22)($1.26)Q2 20244($1.40)($1.17)($1.24)Q3 20244($1.47)($1.19)($1.28)Q4 20244($1.34)($0.71)($1.11)FY 202416($5.55)($4.29)($4.89)Q1 20251($1.22)($1.22)($1.22)Q2 20251($1.24)($1.24)($1.24)Q3 20251($1.07)($1.07)($1.07)Q4 20251($0.87)($0.87)($0.87)FY 20254($4.40)($4.40)($4.40)KROS Earnings Date and InformationKeros Therapeutics last released its quarterly earnings data on March 1st, 2024. The reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business earned $0.14 million during the quarter. Keros Therapeutics has generated ($5.20) earnings per share over the last year (($5.20) diluted earnings per share). Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.11) to ($5.42) per share. Keros Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.Read More Keros Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Estimated)------- 3/1/2024Q4 2023($1.37)($1.34)+$0.03($1.34)-$0.14 million11/6/2023Q3 2023($1.35)($1.33)+$0.02($1.33)-$0.01 million 8/7/2023Q2 2023($1.34)($1.27)+$0.07($1.27)$0.22 million- 5/4/2023Q1 2023($1.14)($1.26)($0.12)($1.26)$0.22 million-3/3/2023Q4 2022($1.12)($1.09)+$0.03($1.09)--11/3/2022Q3 2022($1.26)($0.92)+$0.34($0.92)-- Get the Latest News and Ratings for KROS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($1.07)($1.13)($0.06)($1.13)--5/5/2022Q1 2022($0.86)($1.01)($0.15)($1.01)$4.50 million- 3/9/2022Q4 2021($0.94)($0.30)+$0.64($0.30)-$20.00 million11/4/2021Q3 2021($0.72)($0.87)($0.15)($0.87)--8/5/2021Q2 2021($0.66)($0.67)($0.01)($0.67)-$0.10 million5/6/2021Q1 2021($0.58)($0.68)($0.10)($0.68)-- Keros Therapeutics Earnings - Frequently Asked Questions When is Keros Therapeutics's earnings date? Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on KROS's earnings history. Did Keros Therapeutics beat their earnings estimates last quarter? In the previous quarter, Keros Therapeutics (NASDAQ:KROS) reported ($1.34) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.37) by $0.03. Learn more on analysts' earnings estimate vs. KROS's actual earnings. How much revenue does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $150,000.00. How much profit does Keros Therapeutics generate each year? Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.20 earnings per share over the last four quarters. What is Keros Therapeutics's EPS forecast for next year? Keros Therapeutics's earnings are expected to decrease from ($5.11) per share to ($5.42) per share in the next year. More Earnings Resources from MarketBeat Related Companies: AMPH Earnings RNA Earnings PTCT Earnings MRVI Earnings GLPG Earnings GERN Earnings RCKT Earnings VERA Earnings SDGR Earnings DYN Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:KROS) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
